IndustryCompany release

Apyx Medical lifts Q3 revenue 9% to $14.0m as AYON sales grow

🇺🇸 Apyx Medical Corp (APYX) · Thu 05 Nov 2026

The US device maker reaffirmed its 2026 revenue guidance, lowered its operating expense outlook and began a full commercial launch of its AYON power liposuction handpiece.

Apyx Medical Corp reported third-quarter 2026 results on 5 November, with revenue of $14.0 million, a 9% increase. The company attributed the growth to sales of its AYON body contouring system.

The Surgical Aesthetics segment rose 17% in the quarter, driven by AYON. The OEM segment moved the other way, falling 42%.

Apyx has started a full commercial launch of the AYON power liposuction handpiece, which received FDA clearance earlier in 2026. The source material does not give further detail on the clearance pathway or launch timetable.

The company reaffirmed its 2026 revenue guidance of $59 million to $60 million and lowered its operating expense outlook. No further financial detail was available in the material reviewed.

What it means for your team

  • The new AYON handpiece is moving from FDA clearance to full commercial launch, so post-market surveillance and complaint-handling processes for the product line become more relevant.
  • A 17% rise in Surgical Aesthetics against a 42% fall in OEM shows the company's mix shifting towards its own branded systems.
  • Teams tracking the company should note that full-year revenue guidance of $59-60 million is unchanged, while its operating expense outlook has been cut.

Company's press release (SEC filing): Apyx Medical Corp ↗

Article written by VigiEye from the official source (Apyx Medical Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →